The Complete Guide to Managing GLP-1 Side Effects: Nausea, Fatigue, Constipation, Sulfur Burps, and Injection Reactions
If you've just started semaglutide or tirzepatide — or you're thinking about it — the side effect question is probably front of mind. And honestly? The full picture of what people actually experience is more nuanced than the clinical trial summaries suggest. Most people navigate GLP-1 therapy without serious problems, but the first few months can involve significant GI discomfort, fatigue, and other effects that aren't always well-explained. This guide covers everything: the mechanism behind each side effect, what the research says about frequency and timing, what actually helps, and the red flags that should prompt a call to your doctor.
Why GLP-1 Side Effects Happen: The Core Mechanism
Understanding why side effects occur makes managing them far less mysterious. The root cause of almost all GLP-1 side effects is a single action: slowed gastric emptying.
GLP-1 receptor agonists activate receptors throughout the gastrointestinal tract that slow the rate at which food moves from the stomach into the small intestine. This is intentional — it prolongs the feeling of fullness, moderates post-meal blood sugar spikes, and reduces caloric intake. But slowed gastric emptying is a bit like slowing down a conveyor belt at a food processing plant. Things back up. Food sits in the stomach longer than usual. Bacteria have more time to ferment it. Pressure builds. Gas forms. Motility changes ripple downstream through the intestines.
Additionally, GLP-1 drugs act on the brainstem — specifically the area postrema and nucleus tractus solitarius — which are the same regions that process nausea signals from the gut. This central nervous system activation contributes to nausea independently of the gastric emptying effect.
Understanding this mechanism tells you something important: most GLP-1 side effects are dose-dependent (worse at higher doses, better at lower ones), time-dependent (worst during dose escalation phases, improving over weeks), and diet-sensitive (dramatically worsened by eating patterns that work against slow gastric emptying).
What Reddit Tells Us That Clinical Trials Miss
Clinical trials are incredibly valuable, but they have blind spots. They use structured protocols, selected patient populations, and formal adverse event reporting — which tends to capture textbook side effects but miss the more diffuse, hard-to-categorize experiences that real patients have in real life.
That's why a 2026 University of Pennsylvania study using AI to analyze over 400,000 Reddit posts from nearly 70,000 GLP-1 users is so significant. The findings confirmed known side effects (about 44% of users reported at least one, most commonly GI distress), but also identified two notable categories that clinical trial labels underreport:
-
Reproductive symptoms (approximately 4% of users who reported side effects mentioned menstrual changes — irregular cycles, heavy bleeding, or intermenstrual bleeding). Importantly, the Reddit sample skews male, meaning the true rate among women could be substantially higher.
-
Temperature-related complaints — chills, feeling unusually cold, hot flashes, and fever-like temperature fluctuations. These aren't prominent in prescribing information but emerged as a consistent pattern.
Also notably: fatigue ranked as the second most common complaint overall, despite reaching formal reporting thresholds in relatively few clinical trials. This gap between patient experience and trial capture is exactly what motivates real-world data analysis.
The reported frequency from the Reddit analysis: nausea (36%), fatigue (13.7%), vomiting (12.3%), constipation (15.3%), diarrhea (12.6%).
Part 1: Gastrointestinal Side Effects
Nausea
Frequency: Up to 44–50% of semaglutide users; slightly higher with tirzepatide at therapeutic doses.
Mechanism: Nausea on GLP-1 drugs comes from two directions simultaneously. First, delayed gastric emptying creates gastric pressure and distension. Second, GLP-1 receptor activation in the area postrema (the brain's "vomiting center") directly triggers nausea signals. This is why nausea can occur even when you've eaten very little.
Timing: Worst in the first 4–8 weeks and predictably spikes with each dose escalation. Most patients find it improves significantly after 4–6 weeks at a stable dose. It often peaks 6–24 hours after injection.
Management strategies:
- Eat smaller meals — this is the single most important intervention. The stomach is slow; don't overwhelm it.
- Prioritize protein at the start of meals — it takes longer to digest but produces less fermentation gas than refined carbohydrates.
- Inject in the evening — for many patients, the worst nausea hits 6–8 hours post-injection. An evening injection means sleeping through the worst of it.
- Avoid fatty, greasy, or spicy foods — these already slow gastric emptying on their own. Combined with a GLP-1 drug, they can dramatically worsen nausea.
- Ginger — ginger tea, ginger chews, or ginger capsules have good evidence for reducing nausea across multiple conditions. Many GLP-1 users swear by it.
- Ondansetron (Zofran) — a prescription anti-nausea medication commonly used for chemotherapy nausea. Many prescribers will provide this as a safety net for the early weeks.
- Bismuth subsalicylate (Pepto-Bismol) — over-the-counter nausea relief; works for some patients.
- Avoid lying down immediately after eating — gravity helps; staying upright for at least 30 minutes post-meal improves gastric emptying.
Vomiting
Frequency: Up to 24% of semaglutide users; varies with dose.
Mechanism: An extension of the nausea mechanism. If gastric pressure and brainstem nausea signals become severe enough, vomiting occurs. It's more common in the early weeks and after rapid dose escalation.
When to be concerned vs. normal adjustment:
- Normal: Occasional vomiting in the first few weeks, especially after dose increases; no blood in vomit; able to keep liquids down
- See a doctor: Vomiting persisting beyond 2 weeks at a stable dose, severe dehydration (dizziness, dark urine, inability to keep fluids down), any blood in vomit, severe abdominal pain accompanying vomiting
Constipation
Frequency: 15–30% of users; one of the more persistent side effects.
Mechanism: GLP-1 drugs slow the entire gastrointestinal tract, not just gastric emptying. Reduced gut motility means the colon moves its contents more slowly, water is reabsorbed from stool over a longer transit time, and the result is hard, dry, infrequent stools. This can be one of the longer-lasting GI side effects, sometimes persisting for months.
Management strategies:
- Aggressive hydration: 80–100 oz of water daily. This is non-negotiable and dramatically affects constipation severity. Many GLP-1 users are under-eating and under-drinking simultaneously.
- Dietary fiber increase: Gradually increase soluble fiber (oats, psyllium, beans, fruits) and insoluble fiber (vegetables, whole grains). Start slow to avoid gas and bloating.
- Magnesium: Magnesium oxide or magnesium citrate at 300–500 mg/day is highly effective as an osmotic laxative with minimal side effects. Many GLP-1 users find this is the single most effective constipation intervention.
- Polyethylene glycol (MiraLAX): An osmotic laxative that draws water into the colon. Safe for regular use, evidence-backed, widely recommended.
- Movement: Walking 20–30 minutes after meals stimulates gut motility. Sedentary patients have significantly worse constipation.
- Reduce dose if severe: Constipation that doesn't respond to lifestyle measures is a signal to discuss dose modification with your prescriber.
Diarrhea
Frequency: 12–30% of users; typically early and self-limiting.
Mechanism: Counterintuitively, diarrhea also occurs in a significant fraction of GLP-1 users despite the general "slowing" effect of these drugs. The likely mechanism involves bile acid malabsorption: when gastric emptying slows, bile acids (released by the gallbladder to aid fat digestion) may be poorly reabsorbed in the small intestine and spill into the colon, where they act as osmotic agents drawing in water and accelerating transit. High-fat meals are a particular trigger.
Management: Dietary adjustments (reducing fat content, avoiding trigger foods), hydration, and usually self-resolution within the first few weeks. Bile acid sequestrants (cholestyramine) can help in persistent cases — worth a discussion with your doctor.
Sulfur Burps
Frequency: Commonly reported; exact clinical trial prevalence underestimated due to under-reporting.
Mechanism: Sulfur burps (a particularly pungent, rotten-egg-smelling eructation) are one of the more socially distressing GLP-1 side effects. The cause is straightforward once you understand delayed gastric emptying: food sitting in the stomach for longer than normal undergoes fermentation by resident gut bacteria. Some of these bacteria produce hydrogen sulfide gas as a metabolic byproduct. When that gas is released upward through belching, you get the distinctive sulfur smell. Sulfur-containing foods (eggs, cruciferous vegetables like broccoli and cauliflower, red meat, garlic, onions) dramatically worsen this effect.
Management strategies:
- Avoid eating 2–3 hours before bed: An empty stomach has far less fermentation substrate. Lying down already slows gastric emptying; adding food makes it worse.
- Eliminate sulfur-rich foods temporarily: Eggs, broccoli, cauliflower, Brussels sprouts, garlic, onions, red meat — all high-sulfur foods that fuel bacterial hydrogen sulfide production.
- Small frequent meals: Reduces the fermenting load in the stomach at any given time.
- Simethicone (Gas-X): Reduces gas formation and may help with associated bloating.
- Proton pump inhibitors (PPIs) like omeprazole: If reflux is also a component, PPIs can help by reducing acid backing up through a slower-emptying stomach.
- Pepcid (famotidine): An H2 blocker that some patients find more helpful for the belching component than PPIs.
Gastroparesis Risk
True gastroparesis (clinically significant delayed gastric emptying causing persistent symptoms) is distinct from the transient gastric slowing most GLP-1 users experience. Risk factors for developing drug-induced gastroparesis include:
- Pre-existing diabetic gastroparesis
- Rapid dose escalation
- High doses without adequate titration time
- Female sex and older age
Warning signs requiring evaluation: Persistent nausea and vomiting beyond 2 months at stable dose, significant bloating after even small meals, weight loss exceeding expectations, feeling full after just a few bites for prolonged periods. If anesthesia is planned, be sure your surgical team knows you're on a GLP-1 drug — the FDA has issued guidance about aspiration risk due to delayed gastric emptying.
Part 2: Systemic Side Effects
Fatigue
Frequency: Second most common complaint in the Penn Reddit analysis (13.7% of reporters); underrepresented in clinical trials.
Mechanisms (this one is multi-factorial):
- Caloric restriction effect: When appetite is dramatically suppressed, many GLP-1 users inadvertently eat too little — sometimes only 800–1,200 calories/day. The body responds with fatigue as it conserves energy during a caloric deficit.
- Rapid metabolic adjustment: The body is adapting to using fat for fuel more heavily. This metabolic shift can cause initial fatigue similar to the "keto flu."
- Electrolyte depletion: Inadequate eating and increased water intake without electrolyte replacement can produce hyponatremia (low sodium) and hypokalemia (low potassium) — both of which cause profound fatigue and brain fog.
- Poor sleep quality: Nausea and GI discomfort disrupting sleep compounds daytime fatigue.
Management:
- Prioritize adequate caloric intake (never below 1,200–1,400 kcal/day without medical supervision)
- Electrolyte supplementation: sodium, potassium, and magnesium — consider electrolyte packets designed for this
- Ensure adequate protein (helps maintain energy and lean mass during restriction)
- Evaluate sleep quality
Headaches
Frequency: Common in early weeks.
Mechanism: Almost certainly dehydration-related. GLP-1 drugs suppress appetite for both food and beverages. Many users forget to drink adequately. Combined with the osmotic shifts from rapid weight loss (releasing water stored with glycogen), dehydration headaches are predictable.
Prevention: Proactive hydration, electrolytes, and not relying on thirst cues (which are often suppressed on GLP-1 drugs).
Hair Loss (Telogen Effluvium)
Frequency: Reported by a meaningful fraction of users; not well-captured in clinical trial data.
Mechanism: Hair loss on GLP-1 therapy is a specific type of diffuse shedding called telogen effluvium (TE). Under physiological or nutritional stress — rapid weight loss, inadequate protein, caloric restriction — hair follicles exit the active growth phase (anagen) prematurely and enter the resting phase (telogen). About 3 months later, these hairs shed simultaneously. This is why the hair loss typically begins 3–6 months into GLP-1 therapy, not immediately.
Key points:
- This is not drug toxicity to hair follicles. It's a consequence of rapid weight loss and nutritional stress.
- It is almost always temporary — hair regrows within 3–9 months as the body adapts and nutritional intake stabilizes.
- Prevention: Adequate protein intake (1.2–1.6g/kg/day minimum), biotin supplementation (though evidence is weak), ensuring adequate iron and zinc (both important for hair cycling), and not losing weight too rapidly.
- When to be concerned: Patchy (not diffuse) hair loss, loss persisting beyond 9–12 months, or other signs of thyroid dysfunction (since hypothyroidism also causes TE and may be coincidental).
Menstrual Irregularities
Frequency: Approximately 4% of all Reddit reporters (likely higher in a female-only sample), per the Penn study.
What's reported: Irregular cycles, heavier bleeding, intermenstrual spotting, and in some cases cycle shortening or lengthening.
Hypotheses: Several mechanisms may be at work:
- Rapid fat loss: Adipose tissue stores and produces estrogen. Losing body fat rapidly can alter estrogen levels, disrupting the hypothalamic-pituitary-ovarian axis.
- Insulin sensitivity changes: Improved insulin sensitivity from GLP-1 drugs can alter ovarian hormone dynamics, which may particularly affect women with polycystic ovary syndrome (PCOS) — who are frequently GLP-1 users and may see changes in menstrual regularity as insulin resistance improves.
- Direct GLP-1 receptor effects on reproductive hormones: Less well-studied but theoretically possible given GLP-1 receptor expression in reproductive tissues.
Important note: Improved fertility has been reported in some women on GLP-1 drugs, particularly those with PCOS. Women of reproductive age should not assume GLP-1 therapy prevents pregnancy — contraception should be discussed.
Temperature Sensitivity
The Penn Reddit analysis identified unusual temperature sensitivity — chills, feeling abnormally cold, hot flashes — as an underreported pattern. The mechanism is not definitively established, but hypotheses include:
- Caloric restriction reducing heat production (the body burns fuel to maintain temperature)
- Changes in autonomic thermoregulatory set points mediated by hypothalamic GLP-1 receptor activity
- Rapid changes in adipose tissue (which provides thermal insulation)
Part 3: Rare but Serious Side Effects
Pancreatitis
Risk: Real but rare. GLP-1 drugs carry a class-wide warning for acute pancreatitis. The absolute risk is low, but it exists.
Warning signs: Severe, persistent upper abdominal pain radiating to the back, often accompanied by nausea and vomiting. This is a medical emergency — go to the ER.
Risk factors: Personal or family history of pancreatitis, heavy alcohol use, gallstones, high triglycerides.
Gallbladder Disease and Gallstones (Cholelithiasis)
Risk: Semaglutide increases the risk of gallbladder-related disorders by over 2.5 times, primarily through rapid weight loss. When weight is lost quickly, the liver secretes extra cholesterol into bile, which can crystallize into gallstones. Interestingly, tirzepatide shows less gallbladder risk than semaglutide in comparative data.
Symptoms: Right upper quadrant pain, especially after fatty meals; fever with pain suggests cholecystitis (an emergency).
Thyroid C-Cell Tumors
Context: GLP-1 drugs carry a black box warning for thyroid C-cell tumors (medullary thyroid carcinoma, MTC) based on rodent studies at supraphysiologic doses. This warning is based on rat data, and human relevance is not established. No increase in MTC has been detected in extensive human clinical trial and pharmacovigilance data.
Contraindication: GLP-1 drugs are contraindicated in individuals with personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2). For everyone else, the thyroid cancer risk at human therapeutic doses appears minimal based on current evidence.
Kidney Injury
Mechanism: Dehydration-related. Severely reduced fluid intake combined with GI losses (vomiting, diarrhea) can reduce kidney perfusion. Patients with pre-existing kidney disease need monitoring. Prevention is straightforward: aggressive hydration.
Anaphylaxis and Severe Allergic Reactions
Frequency: Extremely rare. Watch for: hives, difficulty breathing, facial swelling, rapid heart rate shortly after injection. Discontinue the drug and seek emergency care immediately.
Part 4: Injection Site Reactions
Lipohypertrophy
Repeatedly injecting into the same site causes a characteristic fatty lump (lipohypertrophy) that can alter drug absorption. This is entirely preventable with a disciplined rotation protocol.
Rotation protocol: Rotate among the abdomen (avoiding a 2-inch radius around the navel), outer thigh, and upper arm. Within each site, vary the exact spot at least 1–2 centimeters from the previous injection. Keep a simple log if needed.
Minor Site Reactions
Redness, mild swelling, itching, or bruising at the injection site are common and almost always transient. If redness spreads significantly or a lump persists for more than a week, contact your prescriber.
Side Effect Severity Timeline
| Time Period | Common Experience |
|---|
| Week 1–4 | Peak nausea and GI distress; adapting to medication |
| Week 4–8 | GI symptoms often improve at stable dose; constipation may persist |
| Week 8–16 | Significant adaptation; dose escalation brings symptom recurrence |
| Month 3–6 | Hair shedding peaks (telogen effluvium onset); most GI symptoms resolved |
| Month 6+ | Most side effects stabilized; focus shifts to long-term management |
Comparison Table: Semaglutide vs. Tirzepatide Side Effect Frequency
| Side Effect | Semaglutide | Tirzepatide | Notes |
|---|
| Nausea | 44% (high dose) | ~31–45% (dose-dependent) | Both highest at initiation and dose escalation |
| Vomiting | ~24% | ~13–25% | Tirzepatide may have less at lower doses |
| Constipation | ~24–30% | ~17–30% | Both significant; similar management |
| Diarrhea | ~30% | ~17–22% | Semaglutide may have slightly more diarrhea |
| Overall GI events | ~30.8% vs placebo | ~79.8% vs placebo | Tirzepatide shows higher overall GI rate in one comparative analysis |
| Gallbladder disease | 2.5× increased risk | No significant increase | Semaglutide-specific finding |
| Pancreatitis | Rare (class warning) | Rare (class warning) | Both carry this warning |
| Thyroid tumor risk | Rodent data only | Rodent data only | No confirmed human signal for either |
Sources: European Medical Journal GI safety analysis; clinical trial data from STEP and SURMOUNT programs
Frequently Asked Questions
Q: What is the most common side effect of GLP-1 drugs like semaglutide?
A: Nausea is the most frequently reported side effect, affecting up to 44–50% of patients at higher doses. It is caused by two mechanisms: delayed gastric emptying creating stomach pressure, and GLP-1 receptor activation in the brainstem's nausea-processing regions. Nausea is worst during the first 4–8 weeks and during dose escalations, and typically improves significantly at stable doses.
Q: How do you manage nausea on semaglutide or tirzepatide?
A: The most effective strategies include eating smaller, more frequent meals; prioritizing lean protein and avoiding greasy or fatty foods; injecting in the evening so the peak nausea period occurs during sleep; taking ginger (tea, chews, or capsules) for its evidence-based anti-nausea properties; and using prescription ondansetron (Zofran) as needed during the most difficult early weeks. Most nausea improves significantly within 4–6 weeks at a stable dose.
Q: What causes sulfur burps on Ozempic or semaglutide?
A: Sulfur burps occur because delayed gastric emptying causes food to sit in the stomach longer than normal, where gut bacteria ferment it and produce hydrogen sulfide gas. This gas is then released as foul-smelling burps. Management includes avoiding sulfur-rich foods (eggs, cruciferous vegetables, garlic, onions), eating smaller meals, not eating within 2–3 hours of bedtime, and considering simethicone or famotidine for relief.
Q: Why does semaglutide cause constipation and how long does it last?
A: GLP-1 drugs slow motility throughout the entire GI tract, not just the stomach, causing the colon to move its contents more slowly. Water is reabsorbed from stool over a longer transit time, resulting in harder, drier stools. Constipation can persist for weeks to months. Management includes aggressive hydration (80–100 oz/day), dietary fiber, magnesium citrate (300–500 mg/day), and polyethylene glycol (MiraLAX).
Q: Does GLP-1 therapy cause hair loss, and is it permanent?
A: Hair loss (telogen effluvium) occurs in a meaningful fraction of GLP-1 users, typically beginning 3–6 months into therapy. It is caused not by the drug itself, but by the nutritional stress of rapid weight loss and caloric restriction — these stressors push hair follicles into a resting phase, with shedding following 3 months later. It is almost always temporary, with hair regrowth occurring within 3–9 months. Adequate protein intake and not losing weight too rapidly are the best preventive measures.
Q: Can GLP-1 drugs cause menstrual irregularities?
A: Yes — approximately 4% of Reddit users reporting side effects mentioned menstrual changes (irregular cycles, heavy bleeding, or spotting), which may be higher in a female-only sample. The cause is not fully established but likely involves hormonal changes from rapid fat loss, improvements in insulin sensitivity (particularly meaningful for women with PCOS), and possibly direct GLP-1 receptor effects on reproductive hormone regulation. Women of reproductive age should be aware that fertility may also improve, requiring contraceptive consideration.
Q: Is the thyroid cancer warning on GLP-1 drugs relevant?
A: The black box warning for medullary thyroid carcinoma (MTC) is based on rat studies at supraphysiologic doses. No increase in human thyroid cancer has been detected in extensive clinical trials or post-marketing surveillance. The warning remains because the animal findings require acknowledgment, but the absolute human risk at therapeutic doses appears minimal based on current evidence. The drugs are contraindicated in those with personal or family history of MTC or MEN2 syndrome.
Q: What causes fatigue on GLP-1 drugs?
A: Fatigue is multi-factorial on GLP-1 therapy. Key contributors include: inadvertent caloric restriction (eating too little due to appetite suppression), metabolic adjustment as the body shifts fuel utilization, electrolyte depletion from reduced food and fluid intake, and poor sleep from GI discomfort. Management focuses on ensuring adequate caloric and protein intake, proactive electrolyte supplementation, and addressing sleep quality.
Q: When should you go to the ER while on a GLP-1 drug?
A: Seek emergency care for: severe upper abdominal pain radiating to the back (possible pancreatitis), inability to keep any fluids down for more than 24 hours (dehydration risk), severe right upper quadrant pain with fever (possible gallbladder emergency), signs of severe allergic reaction (difficulty breathing, facial swelling, hives), or any blood in vomit.
Q: Do GLP-1 side effects get better over time?
A: Yes, for most people and most side effects. The peak difficulty period is typically the first 4–8 weeks and around each dose escalation. GI symptoms (nausea, diarrhea) usually improve significantly at stable doses. Constipation may persist longer but is manageable. Hair shedding, if it occurs, peaks at 3–6 months and then resolves. The general pattern is one of progressive improvement as the body adapts to the drug's effects on GI motility and appetite regulation.
Q: Does tirzepatide have more or fewer side effects than semaglutide?
A: Both medications have similar side effect profiles. One comparative analysis found higher overall GI event rates with tirzepatide (79.8% vs. 30.8% with semaglutide) in clinical trial populations, though absolute rates vary significantly by dose and trial design. Tirzepatide may cause less gallbladder disease risk than semaglutide. Some patients report subjectively less nausea with tirzepatide despite similar or greater weight loss, possibly due to GIP receptor modulation of gastric function. Individual responses vary considerably.
Key Takeaways
- The root mechanism behind almost all GLP-1 side effects is slowed gastric emptying — food stays in the stomach longer, causing nausea, fermentation, constipation, and reflux.
- Nausea is the most common side effect (up to 44–50%), peaks in the first 4–8 weeks and with each dose escalation, and is significantly managed by small meals, evening injections, ginger, and prescription Zofran.
- Constipation can persist for months — aggressive hydration (80–100 oz/day), magnesium, fiber, and MiraLAX are first-line management.
- Sulfur burps result from bacterial fermentation in a slow-emptying stomach — avoid sulfur-rich foods and don't eat within 2–3 hours of lying down.
- Fatigue is the second most reported complaint in real-world data — often caused by inadvertent caloric and electrolyte restriction rather than the drug itself.
- Hair loss is telogen effluvium (nutritional stress-related), not drug toxicity — it's temporary and peaks at 3–6 months post-therapy initiation.
- Menstrual irregularities affect a meaningful fraction of female users but are underrepresented in clinical trial labeling.
- Serious but rare risks include pancreatitis (seek emergency care for severe back-radiating abdominal pain), gallstones (more common with semaglutide), and kidney injury from dehydration.
- The thyroid cancer warning is based on rodent data only; no confirmed human signal exists at therapeutic doses.
- Injection site rotation prevents lipohypertrophy — use a disciplined multi-site, multi-position rotation protocol.
Citations & References
-
Medical News Today / Penn Study. "Social media data helps AI flag potential risks of GLP-1 medications." 2026. https://www.medicalnewstoday.com/articles/ai-study-reddit-posts-reveals-possible-new-side-effects-weight-loss-drugs
-
Medical Xpress. "AI scans 400,000 Reddit posts to flag overlooked GLP-1 side effects." 2026. https://medicalxpress.com/news/2026-04-ai-scans-reddit-flag-overlooked.html
-
GoodRx. "Semaglutide Side Effects: Management Strategies and More." 2025. https://www.goodrx.com/ozempic/semaglutide-side-effects-management-strategies
-
Ivím Health. "Semaglutide Sulfur Burps: Causes, Symptoms & Tips for Relief." 2025. https://www.ivimhealth.com/semaglutide-sulfur-burps-relief-and-side-effects/
-
SingleCare. "Ozempic sulfur burps and diarrhea: Causes and treatment." 2025. https://www.singlecare.com/blog/ozempic-sulfur-burps-and-diarrhea/
-
European Medical Journal. "Weighing up the Risks: GI Side Effects of Semaglutide vs Tirzepatide." 2025. https://www.emjreviews.com/gastroenterology/news/weighing-up-the-risks-gi-side-effects-of-semaglutide-vs-tirzepatide/
-
TAF Clinic. "Tirzepatide vs Semaglutide Injection: A Detailed Comparison." 2025. https://tafclinic.com.sg/tirztirzepatide-vs-semaglutide-injection-a-detailed-comparison/
-
Fay Nutrition. "Tirzepatide vs. semaglutide: A complete comparison guide." 2025. https://www.faynutrition.com/post/tirzepatide-vs-semaglutide-comparison-guide
-
MedPartners. "How to Manage (or Prevent) Semaglutide Side Effects." 2025. https://www.medpartnerstl.com/post/how-to-manage-or-prevent-semaglutide-side-effects
-
Novo Nordisk. STEP 1 Trial data. Semaglutide 2.4mg weekly for obesity. New England Journal of Medicine. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
-
Eli Lilly. SURMOUNT-1 Trial data. Tirzepatide for obesity. New England Journal of Medicine. 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
